论文部分内容阅读
目的:分析慢性心力衰竭(chronic heart failure,CHF)患者血浆组织因子(tissue factor,TF)和血清血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)的关系,并探讨不同剂量福辛普利对慢性心力衰竭患者的影响。方法:选择30例健康者作正常对照组,35例慢性心力衰竭患者为心力衰竭组,并随机分为常规剂量福辛普利组(10mg每天1次)和中剂量福辛普利组(10mg每天2次),分别在入院时和治疗后10周时检测TF和AngⅡ水平变化;以彩色超声心动图检查左室射血分数(left ventricular ejection fractions,LVEF)和左心室收缩末期容量指数(left ventricular endsystolic volume index,LVESVI)。结果:与正常对照组相比,慢性心力衰竭患者LVESVI,TF及AngⅡ水平明显升高(P<0.01),LVEF值明显降低(P<0.01)。心力衰竭患者TF与AngⅡ呈正相关(r=0.2491,P<0.01)。常规、中剂量福辛普利组治疗后LVESVI,TF及AngⅡ水平较治疗前均有下降(P<0.05或P<0.01),LVEF较治疗前均明显增高(P<0.05或P<0.01),且中剂量组治疗后上述改变更显著(P<0.01)。结论:心力衰竭患者TF与AngⅡ呈正相关关系;福辛普利具有改善心力衰竭患者心功能、对抗血栓前状态的作用,且随着剂量的增加疗效更显著。
Objective: To investigate the relationship between plasma tissue factor (TF) and serum angiotensin Ⅱ (AngⅡ) in patients with chronic heart failure (CHF) and to investigate the effect of different doses of fosinopril on patients with chronic heart failure Impact. Methods: Thirty healthy controls were selected as normal control group and 35 patients with chronic heart failure as heart failure group. Patients were randomly divided into routine dose of fosinopril (10 mg once daily) and mid-dose fosinopril (10 mg The changes of TF and AngⅡ were detected at admission and 10 weeks after treatment respectively. Left ventricular ejection fractions (LVEF) and left ventricular end-systolic volume index (left ventricular ejection fraction, left ventricular ejection fraction, ventricular endsystolic volume index, LVESVI). Results: Compared with the normal control group, the levels of LVESVI, TF and AngⅡ in patients with chronic heart failure were significantly increased (P <0.01), and the LVEF values were significantly decreased (P <0.01). There was a positive correlation between TF and AngⅡ in patients with heart failure (r = 0.2491, P <0.01). The levels of LVESVI, TF and AngⅡ in routine and mid-dose fosinopril groups were significantly lower than those before treatment (P <0.05 or P <0.01), and LVEF were significantly higher than those before treatment (P <0.05 or P <0.01) The above-mentioned changes were more significant in the middle-dose group (P <0.01). CONCLUSION: TF and AngⅡ in patients with heart failure are positively correlated. Fosinopril can improve cardiac function in patients with congestive heart failure and resist the prethrombotic state, and the effect is more obvious with the increase of dose.